[Tissue biomarkers in prostate cancer.]

Area of Science:

• Oncology
• Biomarker Research
• Genomic Medicine

Background:

• Prostate cancer is a leading cause of cancer-related death in men, presenting diverse clinical outcomes.
• Accurate diagnosis and effective treatment of prostate cancer remain significant clinical challenges.
• Emerging biomarkers show promise for improving clinical decision-making, risk stratification, and disease management.

Purpose of the Study:

• To review the role of tissue biomarkers in the diagnosis and treatment of prostate cancer.
• To highlight the potential of biomarkers in precision medicine for prostate cancer.

Main Methods:

• A literature review was conducted on tissue biomarkers for prostate cancer diagnosis and treatment.

Main Results:

• Numerous diagnostic and prognostic tissue-based tests have been developed recently (e.g., ConfirmMDx, Promark, Oncoytype DX, Decipher).
• These tests offer opportunities to enhance the diagnosis, prognosis, and treatment of prostate cancer.
• Tissue biomarkers represent a significant advancement in personalized medicine for prostate cancer.

Conclusions:

• Correct patient stratification is crucial for prostate cancer management to avoid unnecessary procedures in low-risk individuals and optimize treatment for high-risk patients.
• Tissue biomarkers are poised to become essential tools in precision medicine, guiding clinical decisions for prostate cancer.